Japan Approves Biosimilar Teriparatide And Darbepoetin

Japan’s first biosimilar teriparatide has been approved for Mochida Pharmaceutical, while competition in the darbepoetin alfa arena looks set to step up following two recent authorizations.

Bone_Structure
Mochida says it has received Japan's first approval for a biosimilar version of the osteoporosis drug teriparatide • Source: Shutterstock

Mochida Pharmaceutical says it has received the first approval for biosimilar teriparatide issued by Japan’s Ministry of Health, Labor and Welfare. At around the same time, Gene Techno Science and JCR Pharmaceuticals each announced they had received authorizations for darbepoetin alfa biosimilars.

The marketing authorization for Teriparatide BS Subcutaneous Injection Kit 600µg Mochida, previously known as RGB-10, is the result of a...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.